Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Adrian Wiestner

Showing results (91-100 of 149) with videos related to

Pageof 15
Sort By:
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|June 25, 2017
Combined BTK and PI3Kδ Inhibition with Acalabrutinib and ACP-319 Improves Survival and Tumor Control in CLL Mouse ModelCarsten U Niemann, Helena I Mora-Jensen, Eman L Dadashian, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|June 30, 2011
Treatment-induced oxidative stress and cellular antioxidant capacity determine response to bortezomib in mantle cell lymphomaMarc A Weniger, Edgar G Rizzatti, Patricia Pérez-Galán, et al.
Blood|December 1, 2020
Effect of Bruton tyrosine kinase inhibitor on efficacy of adjuvanted recombinant hepatitis B and zoster vaccinesChristopher Pleyer, Mir A Ali, Jeffrey I Cohen, et al.
Diagnostic Microbiology and Infectious Disease|January 26, 2019
Protracted course of disseminated adenovirus disease with necrotizing granulomas in the liverAndrea M Lerner, John E Bennett, Stefania Pittaluga, et al.
Journal for Immunotherapy of Cancer|November 28, 2022
Patient-derived Siglec-6-targeting antibodies engineered for T-cell recruitment have potential therapeutic utility in chronic lymphocytic leukemiaMatthew G Cyr, Maissa Mhibik, Junpeng Qi, et al.
Leukemia & Lymphoma|November 16, 2021
CD5-negative mantle cell lymphoma: clinicopathologic features of an indolent variant that confers a survival advantageArshia Soleimani, Alba Navarro, Delong Liu, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|June 14, 2023
B-cell Receptor Pathway Mutations Are Infrequent in Patients with Chronic Lymphocytic Leukemia on Continuous Ibrutinib TherapyJennifer A Woyach, Paolo Ghia, John C Byrd, et al.
Blood|May 11, 2018
A CD19/CD3 bispecific antibody for effective immunotherapy of chronic lymphocytic leukemia in the ibrutinib eraHannah R Robinson, Junpeng Qi, Erika M Cook, et al.
Blood Advances|February 14, 2022
BTK inhibitors impair humoral and cellular responses to recombinant zoster vaccine in CLLChristopher Pleyer, Kerry J Laing, Mir A Ali, et al.
Blood Advances|February 10, 2022
Circulating tumor DNA predicts therapeutic outcome in mantle cell lymphomaRahul Lakhotia, Christopher Melani, Kieron Dunleavy, et al.
Pageof 15

Showing results (91-100 of 149) with videos related to

Sort By:
Pageof 15
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|June 25, 2017
Combined BTK and PI3Kδ Inhibition with Acalabrutinib and ACP-319 Improves Survival and Tumor Control in CLL Mouse ModelCarsten U Niemann, Helena I Mora-Jensen, Eman L Dadashian, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|June 30, 2011
Treatment-induced oxidative stress and cellular antioxidant capacity determine response to bortezomib in mantle cell lymphomaMarc A Weniger, Edgar G Rizzatti, Patricia Pérez-Galán, et al.
Blood|December 1, 2020
Effect of Bruton tyrosine kinase inhibitor on efficacy of adjuvanted recombinant hepatitis B and zoster vaccinesChristopher Pleyer, Mir A Ali, Jeffrey I Cohen, et al.
Diagnostic Microbiology and Infectious Disease|January 26, 2019
Protracted course of disseminated adenovirus disease with necrotizing granulomas in the liverAndrea M Lerner, John E Bennett, Stefania Pittaluga, et al.
Journal for Immunotherapy of Cancer|November 28, 2022
Patient-derived Siglec-6-targeting antibodies engineered for T-cell recruitment have potential therapeutic utility in chronic lymphocytic leukemiaMatthew G Cyr, Maissa Mhibik, Junpeng Qi, et al.
Leukemia & Lymphoma|November 16, 2021
CD5-negative mantle cell lymphoma: clinicopathologic features of an indolent variant that confers a survival advantageArshia Soleimani, Alba Navarro, Delong Liu, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|June 14, 2023
B-cell Receptor Pathway Mutations Are Infrequent in Patients with Chronic Lymphocytic Leukemia on Continuous Ibrutinib TherapyJennifer A Woyach, Paolo Ghia, John C Byrd, et al.
Blood|May 11, 2018
A CD19/CD3 bispecific antibody for effective immunotherapy of chronic lymphocytic leukemia in the ibrutinib eraHannah R Robinson, Junpeng Qi, Erika M Cook, et al.
Blood Advances|February 14, 2022
BTK inhibitors impair humoral and cellular responses to recombinant zoster vaccine in CLLChristopher Pleyer, Kerry J Laing, Mir A Ali, et al.
Blood Advances|February 10, 2022
Circulating tumor DNA predicts therapeutic outcome in mantle cell lymphomaRahul Lakhotia, Christopher Melani, Kieron Dunleavy, et al.
Pageof 15